Showing 2764 results
-
Press release /Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten…
-
Ad hoc release /Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD)…
-
Press release /Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis…
-
Pulse Update /
-
Pulse Update /
-
Press release /Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If…
-
Press release /Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg…